Provisional figures on participation in the National Immunisation Programme According to RIVM’s registration system, at least 90% of babies have been vaccinated against mumps, measles and rubella (MMR).
More than two million invitations to get vaccinated against HPV in 2023 In early 2023, 1.3 million young adults will receive an invitation to get vaccinated against the human papillomavirus (HPV). This group comprises around 900,000 men and 400,000 women between the ages of 19 and 27.
Annual report ‘Tuberculosis in the Netherlands’ for 2021: slight increase in number of TB patients In 2021, the number of tuberculosis (TB) patients in the Netherlands rose slightly compared to the preceding year: up to 680 TB patients from 622 in 2020. However, the 2021 number was lower than the number for 2019 (754 patients).
New WHO Collaborating Centre hosted by RIVM on Life Course and Health The World Health Organization (WHO) has designated RIVM as WHO Collaborating Centre on Life Course and Health. The Collaborating Centre will support the WHO by contributing to knowledge and research on healthy ageing over the life course. People are growing older all over the world.
Almost half of 9 and 10-year-olds get HPV vaccination at first opportunity This spring, more than 800,000 young people received an invitation to be vaccinated against HPV, the human papillomavirus.
Side effect reports National Immunisation Programme 2021 Last year, the Netherlands Pharmacovigilance Centre Lareb received 1,462 reports of possible side effects from vaccines administered under the National Immunisation Programme. As was the case in previous years, no new, disconcerting side effects have
Participation in National Immunisation Programme shows slight decrease Participation in the National Immunisation Programme has fallen slightly, showing a decrease of 1 to 2 percentage points.
Number of tuberculosis patients in the Netherlands increased slightly in 2021 compared to 2020 The number of people with tuberculosis (TB) in the Netherlands increased slightly in 2021, reaching 680. This figure is 9% higher than it was in 2020 (622 patients).
RIVM expands HPV vaccination programme: girls and boys protected from six types of cancer with one vaccine Now not only girls, but also boys will have the opportunity to protect themselves from cancer caused by HPV.
RIVM to play greater role in tuberculosis control The Committee for Practical Tuberculosis Control (CPT) will be transferred per 1 January 2022 to the National Institute for Public Health and the Environment (RIVM) after a period of 70 years with KNCV Tuberculosis Foundation.